S2TOP-BLEED评分预测非心源性卒中抗血小板治疗患者大出血
研究合并6项随机临床试验的个体患者数据,建立并外部验证抗血小板治疗后TIA或缺血性卒中患者大出血的预测模型S2TOP-BLEED;该评分可估算3年大出血风险,区分度中等,外部验证中略低估风险。
要点
- S2TOP-BLEED评分可估算TIA或缺血性卒中抗血小板治疗患者3年大出血风险。
- 评分区分度有限,开发数据c统计量0.63,外部验证0.61。
- 风险范围从无额外危险因素45-54岁患者的2%到多危险因素75-84岁患者的10%以上。
核心结论
- S2TOP-BLEED评分可基于易获取特征估算TIA或缺血性卒中抗血小板治疗患者的3年大出血风险。
- 模型区分度可能需通过识别更强的大出血预测因素来改善。
研究设计与样本
- 合并6项随机临床试验(CAPRIE、ESPS-2、MATCH、CHARISMA、ESPRIT、PRoFESS)的个体患者数据。
- 按试验分层行Cox回归分析,建立风险预测模型,并在PERFORM试验中外部验证。
- 用c统计量和校准图评估模型表现。
主要发现
- 43,112例患者随访94,833人年期间,1,530例发生大出血。
- 观察到的3年大出血风险为4.6%(95%CI 4.4%-4.9%)。
- 预测因素包括男性、吸烟、抗血小板药物类型(阿司匹林-氯吡格雷)、改良Rankin量表≥3、既往卒中、高血压、较低体重指数、高龄、亚洲 ethnicity、糖尿病。
- 开发数据c统计量0.63(95%CI 0.60-0.64),校准良好;外部验证c统计量0.61(95%CI 0.59-0.63),略低估大出血风险。
- 大出血风险从45-54岁无额外危险因素患者的2%到75-84岁多危险因素患者的10%以上。
关键数值与推荐
- 3年大出血观察风险4.6%(95%CI 4.4%-4.9%)。
- S2TOP-BLEED评分开发数据c统计量0.63(95%CI 0.60-0.64),外部验证c统计量0.61(95%CI 0.59-0.63)。
- 风险范围:45-54岁无额外危险因素者2%,75-84岁多危险因素者超过10%。
临床怎么用
- 对TIA或缺血性卒中且使用抗血小板药的患者,可用S2TOP-BLEED评分基于易获取特征估算3年大出血风险。
- 评分区分度中等且外部验证略低估风险,解读结果时应结合临床判断。
局限性
- 模型区分度有限(c统计量约0.61-0.63),外部验证中略低估大出血风险。
- 需识别更强的大出血预测因素以改善区分能力。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To develop and externally validate a prediction model for major bleeding in patients with a TIA or ischemic stroke on antiplatelet agents. METHODS: We combined individual patient data from 6 randomized clinical trials (CAPRIE, ESPS-2, MATCH, CHARISMA, ESPRIT, and PRoFESS) investigating antiplatelet therapy after TIA or ischemic stroke. Cox regression analyses stratified by trial were performed to study the association between predictors and major bleeding. A risk prediction model was derived and validated in the PERFORM trial. Performance was assessed with the c statistic and calibration plots. RESULTS: Major bleeding occurred in 1,530 of the 43,112 patients during 94,833 person-years of follow-up. The observed 3-year risk of major bleeding was 4.6% (95% confidence interval [CI] 4.4%-4.9%). Predictors were male sex, smoking, type of antiplatelet agents (aspirin-clopidogrel), outcome on modified Rankin Scale ≥3, prior stroke, high blood pressure, lower body mass index, elderly, Asian ethnicity, and diabetes (S2TOP-BLEED). The S2TOP-BLEED score had a c statistic of 0.63 (95% CI 0.60-0.64) and showed good calibration in the development data. Major bleeding risk ranged from 2% in patients aged 45-54 years without additional risk factors to more than 10% in patients aged 75-84 years with multiple risk factors. In external validation, the model had a c statistic of 0.61 (95% CI 0.59-0.63) and slightly underestimated major bleeding risk. CONCLUSIONS: The S2TOP-BLEED score can be used to estimate 3-year major bleeding risk in patients with a TIA or ischemic stroke who use antiplatelet agents, based on readily available characteristics. The discriminatory performance may be improved by identifying stronger predictors of major bleeding.
引用
- Hilkens NA, Algra A, Diener HC, et al. Predicting major bleeding in patients with noncardioembolic stroke on antiplatelets: S2TOP-BLEED. Neurology. 2017. PMID: 28768848. doi:10.1212/WNL.0000000000004289
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。